CXCL10 and COVID-19: A study by E. Terpos et al. study on the first dose of the Pfizer vaccine showed a triggered robust immune response for 50 days in COVID-19-naive recipients, which was also age- and gender-dependent [10,41], as well as a stronger induction in female versus male vaccine recipients of IFN-g, IL-15, IL-6, and IP-10/CXCL10 upon receipt of a second vaccination dose.